作者: Diana B. Petitti , Fagen Xie , Joshua I. Barzilay
DOI: 10.1016/J.CCT.2006.04.010
关键词: Clinical trial 、 Diuretic 、 Health maintenance 、 Angiotensin-converting enzyme 、 Surgery 、 Myocardial infarction 、 Medical prescription 、 Heart disease 、 Internal medicine 、 Thiazide 、 Medicine
摘要: Abstract The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) published its main findings in December, 2002. It recommended thiazide diuretics as a first-line treatment of hypertension. current study describes the prescribing patterns four regions Kaiser Permanente, large national United States Health Maintenance Organizatoin—two that had an ALLHAT clinical center two did not. We tested hypothesis participation trial leads quicker greater adoption recommendations than non-participation trial. relative percentage filled outpatient prescriptions for period 2 or 3 years before publication through December 31, 2004 was calculated by region thiazide-type calcium channel blockers (CCBs), β-blockers, central α-blockers, angiotensin converting enzyme (ACE) inhibitors, receptor (ARBs) other antihypertensive diuretics. In after findings, all increased from 11.2% 12.4% with site 8.9% 10.1% without ( p > 0.05). new 13.7% 16.6% 10.8% 13.0% Participation hypertension does not appear accelerate recommendations.